EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of Pharmacologic Markers of Anti‐Tumor Necrosis Factor‐α Activity and Etanercept Effectiveness in Juvenile Idiopathic Arthritis

Mudassar I Arain iD, Kishore Polireddy, Eduardo S Fricovsky, Mara L Becker, Mohsin Kazi, Ryan S Funk

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Mudassar I Arain und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Program, College of Health and Human Services, University of North Carolina, Wilmington, Wilmington, North Carolina, USA. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Etanercept, Tumor Necrosis Factor-alpha, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NICHD NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapies targeting tumor necrosis factor‐α (TNFα), including etanercept (ETN), have become a mainstay in the treatment of juvenile idiopathic arthritis (JIA). As a result, this work seeks to evaluate the relationship between pharmacologic markers of ETN activity and clinical effectiveness in a cohort of patients with JIA. This is a single‐centered, open‐label, prospective, cross‐sectional study of patients with JIA ( n = 26) receiving maintenance ETN. Determination of ETN effectiveness was based on the absence of active arthritis in any joint at the time of sample collection. Patient plasma samples were collected and analyzed for ETN concentrations, anti‐ETN antibodies, anti‐TNFα activity, and TNFα concentrations. ETN was effective in 46% ( n = 12) of patients assessed at the time of sampling. No differences in baseline demographics were observed between patients based on effectiveness. Median [IQR] plasma ETN concentrations were 2094 [1384, 2680] ng/mL. Anti‐ETN antibodies were undetectable in all patients. Plasma anti‐TNFα activity varied 32‐fold and was directly proportionate to plasma ETN concentrations (ρ = 0.75, p = 3.8 × 10 −3 ). Plasma TNFα concentrations were 9‐fold higher than previous measurements in patients with JIA not receiving anti‐TNFα therapy ( p = 3.6 × 10 −9 ). ETN effectiveness was associated with 21% higher ETN concentrations ( p = 0.36), 52% higher plasma anti‐TNFα activity ( p = 0.14), and 84% higher plasma TNFα concentrations ( p = 0.008). Among pharmacologic markers of ETN activity measured, plasma TNFα concentrations are most strongly associated with ETN effectiveness in JIA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileEtanerceptTumor Necrosis Factor-alphaAntirheumatic AgentsHumansFemaleMaleChildCross-Sectional StudiesProspective StudiesChild, PreschoolAdolescentTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

etanerceptjuvenile idiopathic arthritispharmacokineticstumor necrosis factorbiomarkers

Substanzen

EtanerceptTumor Necrosis Factor-alphaAntirheumatic AgentsBiomarkers

Autor:innen und Institutionen

  • Clinical Research Program, College of Health and Human Services, University of North Carolina, Wilmington, Wilmington, North Carolina, USA.
  • Pharmacy Practice, School of Pharmacy, University of Kansas, Lawrence, Kansas, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, California, USA.
  • Duke School of Medicine, Duke University, Durham, North Carolina, USA.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Riyadh Province, Saudi Arabia.

ORCID-Profile: Mudassar I Arain

Förderung

  • NIH HHS
  • NICHD NIH HHS
  • NIGMS NIH HHS
  • The University of Kansas Clinical and Translational Science Institute
  • Kansas Institute for Precision Medicine
  • NCATS NIH HHS
  • Frontiers Clinical and Translational Science Institute, University of Kansas
  • National Institutes of Health

Zitieren

APA

Arain, M. I., Polireddy, K., Fricovsky, E. S., Becker, M. L., Kazi, M., & Funk, R. S. (2025). Association of Pharmacologic Markers of Anti‐Tumor Necrosis Factor‐α Activity and Etanercept Effectiveness in Juvenile Idiopathic Arthritis. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70166

Vancouver

Arain MI, Polireddy K, Fricovsky ES, Becker ML, Kazi M, Funk RS. Association of Pharmacologic Markers of Anti‐Tumor Necrosis Factor‐α Activity and Etanercept Effectiveness in Juvenile Idiopathic Arthritis. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70166

BibTeX
@article{Arain2025,
  author = {Arain, Mudassar I and Polireddy, Kishore and Fricovsky, Eduardo S and Becker, Mara L and Kazi, Mohsin and Funk, Ryan S},
  title = {Association of Pharmacologic Markers of Anti‐Tumor Necrosis Factor‐α Activity and Etanercept Effectiveness in Juvenile Idiopathic Arthritis},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70166}
}
Kostenlos starten →